Hematopoietic Stem Cell Transplantation
Conditions
Keywords
gender, pediatrics, hematopoietic cell transplantation
Brief summary
Gender medicine considers the way in which gender, male or female, affects the development and impact of diseases and the response to therapies. It can be said that it is a new transversal dimension of medicine, which evaluates the gender differences in the physiology, pathophysiology and clinic of many diseases and thus sets itself the goal of reaching optimal therapeutic decisions both in men and women based on proven scientific evidence. Although knowledge of gender medicine has increased significantly in recent years, a gender approach has not been much developed in pediatrics. In the field of bone marrow transplants, hematopoietic stem cell transplantation is known to be the most effective consolidation therapy in some high-risk hematology malignancies such as acute lymphoblastic leukemia and acute myeloid leukemia, and represents one of the potential treatment for patients suffering from solid tumors and genetic hematological, metabolic diseases and primary immunodeficiencies. Huge progress has been made in high resolution donor typing, choice of conditioning regimens, manipulation of hematopoietic stem cells (HSC) and prevention of serious infections in recent years, which have significantly improved the survival rate of patients undergoing to this procedure. International literature regarding the response and outcomes from hematopoietic cell transplantation in a gender perspective is completely absent, for these reasons this pilot study was born from the need to understand from a broader perspective and in order to better understand how the gender may or not influence the outcome of transplantation in pediatric patients. This retrospective analysis of the data will concern all patients who underwent allogeneic or autologous bone marrow transplant. The data will be collected from clinical records and from Regional electronic databases. All data will be collected anonymously and an identification code will be assigned to each case.
Interventions
PROCEDUREHematopoietic stem cell transplantation
Allogeneic or autologous bone marrow transplant
Sponsors
IRCCS Burlo Garofolo
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
4 Months to 17 Years
Healthy volunteers
No
Inclusion criteria
1. Patients aged between 4 months and 17 years 2. Diagnosis of oncohaematological disease subjected to hematopoietic stem cell transplantation 3. Allogeneic or autologous bone marrow transplantation from January 2000 to October 2018 4. Consent acquired for the processing of data for research purposes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Gender-related difference in overall 12-month toxicity | 12 months after transplant | Differences in toxicity (hepatic, renal, pulmonary, gastrointestinal) in males and females recipients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Gender difference in post-transplant primary disease recurrence | 12 months after transplant | Incidence of post-transplant leukemic relapse in males and females recipients |
| Gender difference in the frequency of transplant-related toxicity at 12 months | 12 months after transplant | Frequency of post-transplant liver, kidney, pulmonary, gastrointestinal, endocrine, cardiac toxicity |
| Gender difference in infectious complications | 12 months after transplant | Number of episodes of sepsis / fungal infections / viral reactivations after HSCT |
| Gender difference in the frequency of adverse events due to pre-transplant conditioning regimen | 12 months after transplant | Number of chemo- radiotherapy-related adverse events. Toxicity was graded according to National Cancer Institute (NCI) common toxicity criteria |
| Gender difference in overall survival (OS) | 12 months after transplant | Overall survival comparison from males and females recipients |
| Gender difference in timing of hematological engraftment | 12 months after transplant | Engraftment defined as the engraftment of polymorphonuclear neutrophils (PMN) on the first day of 3 consecutive days with PMN number greater than 500 / ml3 and engraftment of platelets defined as number of platelets\> 20,000 / ml3 in the absence of platelet transfusion in the previous 5 days. |
| Gender difference in frequency of primary graft failure | 12 months after transplant | Engraftment defined as the engraftment of polymorphonuclear neutrophils (PMN) on the first day of 3 consecutive days with PMN number greater than 500 / ml3 and engraftment of platelets defined as number of platelets\> 20,000 / ml3 in the absence of platelet transfusion in the previous 5 days. Primary graft failure is defined as no evidence of engraftment or hematological recovery of donor cells, within the first month after transplant, without evidence of disease relapse. |
| Gender difference in frequency of secondary graft failure | 12 months after transplant | Engraftment defined as the engraftment of polymorphonuclear neutrophils (PMN) on the first day of 3 consecutive days with PMN number greater than 500 / ml3 and engraftment of platelets defined as number of platelets\> 20,000 / ml3 in the absence of platelet transfusion in the previous 5 days. Secondary graft failure refers to the loss of a previously functioning graft, resulting in cytopenia involving at least two blood cell lineages. |
| Gender difference in severity of adverse events due to pre-transplant conditioning regimen | 12 months after transplant | Severity of chemo- radiotherapy-related adverse events. Toxicity wil be graded according to National Cancer Institute (NCI) common toxicity criteria |
Outcome results
None listed